Cardlytics, Inc. (NASDAQ:CDLX) Shares Acquired by Barclays PLC

Barclays PLC grew its stake in Cardlytics, Inc. (NASDAQ:CDLX) by 223.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,026 shares of the company’s stock after purchasing an additional 40,112 shares during the period. Barclays PLC owned approximately 0.11% of Cardlytics worth $186,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RBF Capital LLC boosted its position in Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after purchasing an additional 369,620 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after acquiring an additional 354,474 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock valued at $2,882,000 after acquiring an additional 307,800 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Cardlytics by 56.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 317,644 shares of the company’s stock valued at $1,016,000 after acquiring an additional 113,966 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after acquiring an additional 73,484 shares in the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

Insider Buying and Selling

In other news, CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the sale, the chief financial officer now owns 116,481 shares of the company’s stock, valued at $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 46,400 shares of company stock worth $164,260 in the last three months. 4.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. Finally, Evercore ISI initiated coverage on Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.92.

Cardlytics Stock Up 2.1 %

CDLX opened at $3.47 on Thursday. Cardlytics, Inc. has a 12 month low of $2.76 and a 12 month high of $20.52. The stock has a market cap of $176.35 million, a P/E ratio of -0.57 and a beta of 1.53. The stock’s 50 day moving average price is $3.64 and its 200 day moving average price is $4.42. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. During the same period last year, the firm earned ($0.26) EPS. The firm’s revenue for the quarter was down 15.1% on a year-over-year basis. As a group, research analysts predict that Cardlytics, Inc. will post -1.52 earnings per share for the current year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.